Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide

Clinical Neurology and Neurosurgery
Emel YamanRamazan Yildiz

Abstract

Temozolomide is the major drug in the treatment of malignant gliomas. Radiation induced necrosis can behave radiologically and clinically like a recurrent tumor. The major problem is the differentiation between recurrence and radiation injury especially in early phases of treatment. The aim of this study was to evaluate the patients receiving temozolomide showing early clinical or radiological progression and impact of early necrosis on follow-up. We retrospectively evaluated medical records of 67 patients with malignant glioma receiving temozolomide. All patients received concomitant radiotherapy and temozolomide followed by adjuvant temozolomide. In case of any radiological or clinical progression, MRI spectroscopy evaluation was used to confirm tumoral progression. Radiological or clinical progression was observed in 17 (25.4%) patients. Early radiation induced necrosis was diagnosed in 4 of 17 patients (23.5%) by surgery (n=3) and MRI spectroscopy (n=1). The observed incidence of pseudoprogression was 4 in 67 (6%) patients. Patients with diagnosis of early radiation injury had median progression-free survival of 7 months compared to 5 months in patients without radiation damage (p=0.004). However, there was no statistically...Continue Reading

References

Dec 1, 1996·International Journal of Radiation Oncology, Biology, Physics·J S TaylorR L Heideman
Jul 17, 2003·The Neurologist·Pierre Giglio, Mark R Gilbert
Oct 13, 2004·The Oncologist·Diego J CovarrubiasMichael H Lev
Nov 24, 2005·AJR. American Journal of Roentgenology·Patrick WeybrightLarry Junck
Feb 10, 2007·International Journal of Radiation Oncology, Biology, Physics·Qing-Shi ZengDe-Chao Feng
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba A BrandesMario Ermani
May 3, 2008·The Lancet Oncology·Dieta BrandsmaMartin J van den Bent
Sep 1, 2009·Clinical Neurology and Neurosurgery·Deok-Joo RheeDo-Hyun Nam

❮ Previous
Next ❯

Citations

Dec 26, 2012·Magma·Andreas KjærLiselotte Højgaard
May 15, 2013·Journal of Neuro-oncology·Graeme F WoodworthPeter C Burger
Feb 22, 2012·Current Neurology and Neuroscience Reports·James FinkMarc C Chamberlain
Mar 15, 2011·American Journal of Clinical Oncology·Erkan TopkanBerrin Pehlivan
Jul 6, 2014·International Journal of Molecular Sciences·Kashif ParvezGelareh Zadeh
Mar 19, 2014·Acta Oncologica·Ioanna ChronaiouTone Frost Bathen
Mar 24, 2012·Neurosurgery Clinics of North America·Arman Jahangiri, Manish K Aghi
Dec 5, 2012·Acta Neurologica Scandinavica. Supplementum·K M Knudsen-BaasA Storstein
Nov 7, 2017·Cancer Medicine·Carmen BalañaUNKNOWN GLIOCAT Group
Apr 3, 2013·Expert Review of Neurotherapeutics·Tim J KruserH Ian Robins
Nov 27, 2015·Journal of Neuro-oncology·Hun Ho ParkJong Hee Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christina I TsienBrian D Ross
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
E Van MieghemP M Clement
© 2021 Meta ULC. All rights reserved